Modification of Vascular Disease Markers in Active Rheumatoid Arthritis with Fully Human Monoclonal Anti-TNF-alpha Antibody (Humira [Adalimumab])

Trial Profile

Modification of Vascular Disease Markers in Active Rheumatoid Arthritis with Fully Human Monoclonal Anti-TNF-alpha Antibody (Humira [Adalimumab])

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Feb 2015

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Pharmacodynamics
  • Acronyms MARVEL
  • Most Recent Events

    • 28 Feb 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top